Evidence map›Paper›PMID 21217128›Full record

ArticleThe Journal of antimicrobial chemotherapy2011

Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures.

P J Johnsen, J P Townsend, T Bøhn, G S Simonsen, A Sundsfjord, K M Nielsen

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Multidrug-Resistant Bacteria in the Community: An Update.Infectious disease clinics of North America · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Antimicrobial Resistance inMicrobiology spectrum · 2018
    Review
  9. Review
  10. Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned.Infectious disease clinics of North America · 2016
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

P J JohnsenDepartment of Pharmacy, Faculty of Health Sciences, University of Tromsø, 9037 Tromsø, Norway. paal.johnsen@uit.no
J P Townsend
T Bøhn
G S Simonsen
A Sundsfjord
K M Nielsen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo estimate the relative fitness differences between glycopeptide-resistant Enterococcus faecium (GREF) and glycopeptide-susceptible E. faecium (GSEF) from yearly surveillance data on the occurrence of GREF in Danish poultry farm environments.

methodsA population genetic model was adapted to retrospectively estimate the biological fitness cost of acquired resistance. Maximization of a likelihood function was used to predict the longitudinal persistence of acquired resistance.

resultsOur analysis suggests strong selection against GREF following the 1995 ban on the glycopeptide growth promoter avoparcin. However, parameterizing the model with two selection coefficients suggesting a reduced negative effect of the acquired resistance on bacterial fitness over time significantly improved the fit of the model. Our analyses suggest that the acquired glycopeptide resistance will persist for >25 years.

conclusionsAcquired resistance determinants in commensal E. faecium populations in Danish farm environments are likely to persist for decades, even in the absence of glycopeptide use.

Indexed as

Vancomycin ResistanceAnimalsAnti-Bacterial AgentsCarrier StateDenmarkEnterococcus faeciumGlycopeptidesGram-Positive Bacterial InfectionsPoultryAnti-Bacterial AgentsGlycopeptides

Identifiers

PMID21217128
PMCPMC3037156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.